CMV-Reactivation after allogeneic Bone Marrow Transplantation Approval of the Drug Letermovir recommended in the EU

被引：0
|
作者：
不详
机构：
来源：
TRANSFUSION MEDICINE AND HEMOTHERAPY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：430 / 430
页数：1
相关论文
共 50 条
  • [1] CMV-Reactivation after allogenic Bone Marrow Transplantation New Active Substance Letermovir approved in EU
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (02)
  • [2] RISK FACTORS OF CMV-REACTIVATION AND THE INFLUENCE OF CMV-REACTIVATION ON RISK OF LEUKEMIA RELAPSE IN CHILDREN AND ADOLESCENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Shiriaev, S.
    Chukhlovin, A.
    Vavilov, V.
    Stancheva, N.
    Barkhatov, I.
    Zubarovskaya, L.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S463 - S463
  • [3] Letermovir prophylaxis reduces the risk for CMV reactivation after allogeneic stem cell transplantation
    Koch, K.
    Herhaus, P.
    Osswald, L.
    Braitsch, K.
    Bassermann, F.
    Verbeek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 62 - 62
  • [4] Prophylaxis of CMV Infections after Bone Marrow Transplantation Letermovir in Phase Ill Trial successful - Application submitted for Approval
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (04)
  • [5] Prevention of cytomegalovirus (CMV) reactivation by standard dose valacyclovir (VACV) after allogeneic bone marrow transplantation
    Mori, T
    Shimizu, T
    Aisa, Y
    Ikeda, Y
    Okamoto, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 30 - 30
  • [6] RISK FACTORS FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND INITIAL EXPERIENCE WITH LETERMOVIR PROPHYLAXSIS
    Sperotto, A.
    Candoni, A.
    Cerno, M.
    De Marchi, R.
    Cigana, C.
    Radici, V.
    Battista, M. L.
    Colasante, F.
    Rosignoli, C.
    Dubbini, V.
    Stella, R.
    Geromin, A.
    Patriarca, F.
    Fanin, R.
    HAEMATOLOGICA, 2019, 104 : 131 - 131
  • [7] CMV and EBV Reactivation after Allogeneic Transplantation
    Butler, Andrew
    Thurston, Andrew
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S244 - S244
  • [8] Risk factors for CMV reactivation after T-cell depleted allogeneic bone marrow transplantation.
    Lin, TS
    Zahrieh, D
    Weller, E
    Alyea, ER
    Fisher, DC
    Gribben, JG
    Freedman, AS
    Schlossman, RL
    Lee, SJ
    Antin, JH
    Ritz, J
    Soiffer, RJ
    BLOOD, 2001, 98 (11) : 480A - 481A
  • [9] Prophylaxis of CMV-Infections after Bone Marrow Transplantation Letermovir successful in Phase-III-Study - Application for Approval submitted
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11)
  • [10] Multipotent Vδ2-Negative γδT-Cells after CMV-Reactivation in Allogeneic Stem Cell Transplantation
    Scheper, Wouter
    van Dorp, Suzanna
    Sebestyen, Zsolt
    Kersting, Sabina
    Pietersma, Floor
    Hol, Samantha
    Marcu-Malina, Victoria
    Becke, Sabina
    Plachter, Bodo
    van Baarle, Debbie
    Kuball, Jurgen
    MOLECULAR THERAPY, 2012, 20 : S185 - S185
12345